Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors
Go back to Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors| SORRENTO THERAPEUT (NASDAQ: SRNE) | Delayed: 0.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.31 | 52 Week High | $10.26 | |||
| Open | $0.31 | 52 Week Low | $4.25 | |||
| Day High | $0.31 | P/E | N/A | |||
| Day Low | $0.31 | EPS | $-0.50 | |||
| Volume | 334,253 | |||||
